Accreditation and Acknowledgementtherapies is noted within the slide presentation. Planner...

transcript

Accreditation and Acknowledgement

§ Forefront Collaborative designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™; physicians should claim only the credit commensurate with the extent of their participation in the activity

§ Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians

§ The activity is provided by Forefront Collaborative and supported by an educational grant from Lilly

Faculty Disclosures§ In compliance with ACCME and AMA guidelines, faculty disclosures will be

acknowledged prior to his or her slide presentation

§ When providing information, in whole or in part, related to non-FDA approved uses for drug products and/or devices, the presenter will clearly acknowledge the unlabeled indications or the investigative nature of their proposed uses to the audience

§ Acknowledgement of unapproved uses or the investigational nature of therapies is noted within the slide presentation

Planner DisclosuresEducational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. The reviewers of this activity have no relevant financial relationships to disclose.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:§ Planner (Forefront Collaborative): Katie Detzler

Planner Disclosures (cont.)The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:§ Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has personal stock in Teva

Pharmaceutical Industries § Planner: Stewart Tepper, MD, has received salary from Dartmouth-Hitchcock Medical Center and from the

American Headache Society and royalties from Springer; he has been a consultant or on an advisory board for Acorda Therapeutics, Alder BioPharmaceuticals, Alexza Pharmaceuticals, Allergan, AlphaSights, Amgen, Autonomic Technologies, Axsome Therapeutics, Cefaly, Charleston Laboratories, DeepBench, Dr. Reddy’s Laboratories, electroCore, Eli Lilly and Company, eNeura, GLG Pharma, Guidepoint Global, Magellan Rx Management, Neurolief, Nordic BioTech, Novartis, Pfizer, Scion NeuroStim, Slingshot Insights, Supernus Pharmaceuticals, Teva Pharmaceutical Industries, and Zosano Pharma Corporation; Dr. Tepper has contracted research for Alder BioPharmaceuticals, Allergan, Amgen, Autonomic Technologies, Dr. Reddy’s Laboratories, electroCore, eNeura, Neurolief, Novartis, Scion NeuroStim, Teva Pharmaceutical Industries, and Zosano Pharma Corporation; he has ownership interest in Autonomic Technologies

Planner Disclosures (cont.)The following individuals have disclosed that they and/or their spouse/partner has had a financial

relationship in the past 12 months:

§ Reviewer: Deborah Friedman, MD, has been a consultant or on an advisory board for Alder

BioPharmaceuticals, Allergan, Amgen, Biohaven Pharmaceuticals, electroCore, Promius, Supernus

Pharmaceuticals, Teva Pharmaceutical Industries, and Zosano Pharma Corporation; she has been a

speaker for Allergan, Amgen, electroCore, Supernus, Autonomic Technologies, and Teva Pharmaceutical

Industries; she has received clinical trial grant support from, Axon Optics, Autonomic Technologies, Eli Lilly

and Company, Merck, and Zosano Pharma Corporation

§ Reviewer: Lawrence Newman, MD, has contracted research for Alder BioPharmaceuticals, Allergan,

Amgen, Eli Lilly and Company, and Teva Pharmaceutical Industries

§ Reviewer: Todd Schwedt, MD, has consulted or been on an advisory board for Alder BioPharmaceuticals,

Allergan, Amgen, Cipla, Eli Lilly and Company, Ipsen, Dr. Reddy’s Laboratories, Novartis, and Teva

Pharmaceutical Industries; Dr. Schwedt has contracted research for Amgen; he has ownership interest in

Aural Analytics, Nocira, and Second Opinion

How to Claim Credit§ To claim CME credit, you will have to complete the evaluation form located at

your seat and return the program to a staff member at the end of this activity § Please write in (last page) if you are claiming AOA credit

Claiming AOA credit

How to Claim Credit (cont.)§ The pre- and posttest are also located at your seat. If you have not completed

the pretest, please do so now § There will be some time at the end of the activity for you to complete the posttest

Slides and Question Cards§ The slides presented during this symposium can be downloaded at forefrontcollabactivities.com/RethinkingMigraine

§ Question cards are in the center of your table; they will be collected throughout the presentation § The question and answer session will begin following the last presentation § Please hand the question cards to a staff member as they walk around the room

§ As a courtesy to others, please silence your cell phones or set them to vibrate

!"#$%#&$#'($!"#$%&'(%)*#+'*(+$*)+

!"##$%!&'"(")*%+,*%-./0,-./012.3#45..26#7/58509/#:.2;.5<,-./012.#%=>51-/=1#)/?.2@2;A3#B1C#D2E/>9FE#72E>-15@#5=8#$/8-05@#G/=1/.45..26#)/?.2@2;-05@#%=E1-1?1/:92/=-H3#(.-I2=5

!"#$%&'()*+#%,+$-.+

Kerry Knievel, DO

#/01234504657891/:;(</5:7=!""#$%&'()!*%#'()&'+),-./&0#' 1/&$*&2#34-2&"5)

+>?5@?:=(((!""#$%&')&'+)!*%#'

#/04:5A4?7(:?1?5:AB=!"+#$),-.1/&$*&2#34-2&"5()!""#$%&'()&'+)!*%#')

!"#$%&

Case 1! !" #$%&"%'%()*+,'-*./0%1.2'3%1&45%

0,6-,""&.37%'38&,4+7%9'+3':0;"%0&",'",7%'30%5,'0'<5,"%"&3<,%<5&/05..0

! =5,%'44'<>"%.<<:-%1,,>/+%'30%'-,%?,3,-'//+%(%0'+"%&3%0:-'4&.3

! =5,+%'-,%.@4,3%4-&??,-,0%A+%"4-,""7%@'4&?:,7%'30%2,3","

! B,'0'<5,"%'-,%6-,<,0,0%A+%'%6-.0-.2,%.@%C%0'+%.@%<.?3&4&D,%@:EE&3,""%'30%2'/'&",%A:4%3.%4-:,%':-'

F#GD&4'/%"&?3"$%HIGA/..0%6-,"":-,$%IG6:/",$%9G-,"6&-'4.-+%-'4,$

Case 1 (cont.)! !"#$%$&"'"#$&%'"(%)*%"##+,-".)&'%/(%

0$1+//).23%/)4"0&1"4%,+'&1"0&%0+%*&5&1&%-").3%-$+0+6 ".'%-$+.+-$+/)"3%".'%."7*&"%8)0$%91&:7&.0%')*"/)4)0(%".'%8+1;%4+**

! <=>%?@%ABCDEC3%@%EB3%F%ABG%#+,-4&0&%,&')#"4%".'%.&71+4+2)#%&H",*%"1&%.+1,"4

! I#70&4(3%*$&%2&0*%1&4)&9%8)0$%*7,"01)-0".%ACC%,2%@J%/70%7*7"44(%$"*%1&#711&.#&%0$"0%1&:7)1&*%1&01&"0,&.0

! K+1%-1&5&.0)+.3%*$&%$"*%01)&'%",)01)-0(4).&3%8$)#$%#"7*&'%&H#&**)5&%*&'"0)+.3%".'%0+-)1","0&3%8$)#$%#"7*&'%8+1'69).').2%')99)#740(

<=L5)0"4%*)2.*M%?@L/4++'%-1&**71&M%@L-74*&M%FL1&*-)1"0+1(%1"0&M

!"#$%&

Case 2! !" #$%&"%'%()*+,'-*./0%1.2'3%1&45%0,6-,""&.37%'38&,4+7%

5,'0'95,"%"&39,%95&/05..07%'30%'99,/,-'4&3:%;-,<=,39+%".%45'4%"5,%5'"%5'0%5,'0'95,%>?)%0'+"%6,-%2.345%;.-%>(%5.=-"%6,-%0'+%;.-%>?@%+,'-"

! A5,%5'"%2&:-'&3,%'30%'"".9&'4,0%;,'4=-,"%>B%0'+"%6,-%2.3457%45'4%&"%0'+"%.;%2.0,-'4,%4.%",C,-,%D&/'4,-'/%45-.DD&3:%6'&37%65.4.* '30%65.3.65.D&'7%3'=",'7%'30%".2,4&2,"%C.2&4&3:

! A5,%&"%="&3:%4-&64'3"%'30E.-%FGH%9.2D&3'4&.3%'3'/:,"&9"%;.-%>?)%0'+"%6,-%2.345

!IJK2':3,4&9%-,".3'39,%&2':&3:$%!ILK2':3,4&9%-,".3'39,%'3:&.:-'2$%!IMK2':3,4&9%-,".3'39,%C,3.:-'65+$%GNG"K45+-.&0%;=394&.3%4,"4"$

Case 2 (cont.)! !"#$"%&$%$"'&()*+$),$%$-.##/'01$1%&(*'2$3.2#*$-3($'&$&('..$3&'01$("#$%&4'*'05%2#(%6'0)4"#052%,,#'0#$7889:$2)6-'0%(')0$(%-.#(&$34$()$;$4#*$/%+$<'("$)*$<'(")3($(*'4(%0&

! !"#$*#2#0(.+$())=$%$(#64)*%*+$.#%>#$,*)6$<)*=?$0)$.)01#*$%-.#$()$,)23&$)*$,302(')0$)0$6%0+$/%+&$4#*$6)0("

! @!A$BC$DEFGHI?$C$HJ?$K$DJ?$%0/$("#$*#&($),$"#*$2)64.#(#$6#/'2%.$%0/$0#3*).)1'2$#L%6$'&$0)*6%.

! MKN$<'(")3($2)0(*%&(?$MK8?$MK@?$OPO&?$Q+6#$('(#*&?$'0,.%66%()*+$6%*=#*&$%..$0)*6%.

MKNR6%10#('2$*#&)0%02#$'6%1'01S$MK8R6%10#('2$*#&)0%02#$%01')1*%6S$MK@R6%10#('2$*#&)0%02#$>#0)1*%4"+S$OPO&R("+*)'/$,302(')0$(#&(&S

Case 2 (cont.)! !"#$"%&$'(&'))#&&*'++,$-./#0$%-$+#%&-$12$0/**#.#(-$3#0/)%-/4(&

! !"#$#%&'(%)&"'*+,)'%-+./#/0

! 1"'-2-+'-,)56$73/-./8-,+/(#$96$:4.-./8-,+/(#

! 3456,)16$;#(+%*%</(#$=6$>'+4<#-/(#

! 7#&*)8+(-9#",)?6$@.48.%(4+4+$A6$B#-48.4+4+

! :*+-'.;)-<*%%#+)8+(-9#",)C6$;#.%8%3/+D6$73+40/8/(#

! =:>)'%<'8'&(",)E6$F/&/(48./+

! =57,526$G%(0#&%.-%(

! =>?,)556$H48/.%3%-#596$I4(/&%3/0#516$>/J%+8.4#<5=6$K%L%8#(-/(5?6$@.#M%L%+/(

Case 2 (cont.)! !"#$"%&$'(&'))#&&*'++,$-./#0$%-$+#%&-$12$0/**#.#(-$3#0/)%-/4(&

! !"#$%&$'()*+&(,"*#-%-.

! /'(0$),+56$!'3%-./7-%(86$94+3/-./7-%(16$:/;%-./7-%(<6$=+#-./7-%(>6$?%.%-./7-%(

! 12!34+&@6$AB'7.4*#(C6$D&7/./($%+4(#$%(0$DDEF6$?%7.4G#($&40/'3H6$!4+'B/+/;#0$0/)+4*#(%)526$I#-4.4+%)556$J#+4G/)%3586$E#+#)4G/B

! 5'67$+516$KL=$(%&%+$&7.%,$

! 8(+"%**),%7#+5<6$M/;%(/0/(#5>6$J#-4)+47.%3/0#

!"#$%#&$#'($!"#$%&'(%)*#+'*(+$*)+

!"#$%&'(")*+, -&./$0'120'34(-,-./.01-#"-22345167#893:9.;#<69-0=39>(5565=.?=#893@-5539#3@#)-A9323:B>$.B3#C26?60813-?6D>#(96E3?.

!"#$%&'()*+#%,+$-.+

#/01234504657891/:;(</5:7=!""#$%&'()!*%#'()&'+),-./&0#' 1/&$*&2#34-2&"5)

Rashmi Halker Singh, MD, FAHS

OVERVIEWThe New Era of Migraine Treatment

! !"#"$%&'()'$#"*&+$&,$("-*%'$(+$.&/+.-'+$"&0'%12013*+242.3! 5/0'#%&26&"0+*2(+#&'$(&#1-2$+#&/+.-'+$"&%2&7,'4+%3&26&4+6"&! 8$/"%&0'%+"$%&$""(*&! 9":&'$(&"/"-.+$.&%-"'%/"$%*&+$&'#,%"&'$(&0-")"$%+)"&%-"'%/"$%&26&/+.-'+$"&! ;2$%-'*%&%2&#,--"$%&*%'$('-(*&26&#'-"&! 5("$%+63&"$(02+$%*&/"'$+$.6,4&%2&#4+$+#'4&0-'#%+#"<&12:&%-"'%/"$%&*,##"**&'$(&6'+4,-"&*12,4(&="&/"'*,-"(&

!"#$%!$&'(%)%*&!"# $%&'!(&)$*+,$!'-&$.

Migraine Pathophysiology

!"#$%&'(&)*+,),-./,/01/('*/2-3/3*)2/4-56!%*1)./7),'(-,8&(/89-&'82'()94:2'3*/2-;)*<-3/17)99)+,-=1+7-"+'29>? $@A-/*-'(4 !"#$%& '"()*4-BCCBDEFGHBIJKBJC4

Summary of Pathophysiology and Targets

!"#$%&'()#% *+,-.-/#01+/234#53-+#/23+67-66-8+

!"#$%&'()*+,+-./)0123404-+50/6789:;/20<0=.0

!"#$%>'?=.3@3).-2+@-+3)

!"#$%A'()*+,+-./@0)-2=</4=+)/-2=).B+..+3)

!"#$%&'&0@20=.0./4=+)/.+C)=</-2=).B+..+3)

!"#$%!"&'()*+',)'-,./01234(.-,2(5.1(56-(.,2(57)*/5#.)8)2.92:5;<=5>&2-&2.)(5>?35!"#$%$&'()*+ ,-.35@AAABCD5E:6--FGHI>@CJ>@A3

Pathophysiology and Treatments! !"#$%"&'()%"&("*(+,-./%0'-(12($'/'%*'(,3(4567(%&-(,08'$(&'.$,)')0"-'*(9"08($'*./0%&0(+'&"&#'%/(:%*,-"/%0",&(%&-(&'.$,#'&";("&3/%++%0",&

! 4.$$'&0(+"#$%"&'<*)';"3";(%;.0'(0$'%0+'&0*(%$'(*'$,0,&"&(=><?@ABCDE %#,&"*0*(08%0("&8"1"0(4567($'/'%*'F(;,&*0$";0(4567<-"/%0'-(:'**'/*F(%&-()$':'&0()%"&(*"#&%/*(3$,+($'0.$&"&#(0,(08'(1$%"&G(08'2(%$'(;,&0$%"&-";%0'-(9"08(:%*;./%$(-"*'%*'

! H$%/()$':'&0":'(+'-";%0",&*(%$'(;'&0$%//2(%;0":'F(+,-./%0"&#(;'&0$%/(+"#$%"&'("&0'#$%0",&

! @%$#'0*(0,(0'$+"&%0'(,$()$':'&0(+"#$%"&'("&;/.-'(><?@BCDEFI %#,&"*0*(=0$")0%&*F('$#,0*F(/%*+"-"0%&A(%&-(4567(%&0%#,&"*0*(=#')%&0* %&-(+,&,;/,&%/(%&0"1,-"'*A

Worldwide Migraine Impact! !"#$%&'(#)*+#,-./0#1+2/)*#3.42"562)5-"#/57)+0#854.25"+#9'#-:#)*+#&%#4.+2)+7)#;2<7+7#-:#=+2.7#/5>+0#?5)*#0572@5/5)=#ABCD7E

! F54.25"+#?27#&#-:#)*+#$#/+205"4#;2<7+7#-:#BCD7#5"#0+>+/-G+0#;-<").5+7(#2"0#5"#)*+#)-G#H#?-./0?50+

! IF54.25"+(#5";/<05"4#8+05;2)5-"#->+.<7+#*+202;*+(#2#;-8G/5;2)5-"#-:#;*.-"5;#854.25"+#AJFE(#*27#@+;-8+#)*+#7+;-"0K/2.4+7)#;2<7+#-:#0572@5/5)=#5"#$%&'L

MND#$%&'#D57+27+#2"0#!"O<.=#!";50+";+#2"0#P.+>2/+";+#J-//2@-.2)-.7Q#!"#$%&Q#$%&RSTU%A&%&%%EV&$&&K&$HUQ

"'()*+,- #!'()*+,-

Adherence to Oral Migraine Preventives Is Poor! ./+0)-1/2+34/'2563(-'76+686-/'6*659-3-:';*-<0/7'16+3/*+-'=3+,'(3>063*/'6*7'?#&',/6762,/'769-@()*+,'ABCD"DDE

F6+3/*+-'G7,

+'+)'H065'F

956I3-J'K

!"#$%&'"&()*+,)-)&'"-)*',).'/)&'*%-),*'0)*$%(,#)*%1*2*3).,456

L/11 MJ'/+'65N'!"#$%&%&'(%N'!%#&OP&:Q$DRQDDN

Reasons Patients Discontinue Prophylactic Medication: Unmet Need is High! !"#$%"&#'("&)*+,%-$"*(.*/'0%&'"$*1#,-23!!*&44$44$-*5%$6$"#'6$*#7$%&52*5&##$%"4*'"*889:*5&#'$"#4*;'#7*<'0%&'"$

A&#'$"#4B*C

!"#$%&"'#()*+),%(-.#$(/ 0"'1+(&+,&&$'"'* !$2,+,&&,'#% 3(%# 4#5,)

!"#$%&'(&))*"#)+,"-./01!"#$&'$2&'#$3)+,"-4.015672839&()+,"-4./1:*23$;<+3=*""&2+72839&()+,"-0>1

?*39+8@+&@@$3*3A+*"%B8(+<&%$3*#$8"+)$%&+&@@&3#)+*(&+#=&+<8)#+38<<8"+(&*)8")+@8(+%$)38"#$";*#$8"+8@+'(&C&"#$C&+<&%$3*#$8")D

E*#$&"#6F&'8(#&%+F&*)8")+@8(+G$)38"#$";*#$8"+8@+E(8'=A2*3#$3+H&%$3*#$8"

+),<$".$)-*D/B*$#*&)E*!"#$#%&"E*>=8?F:?G@HI9@@J9::E

!"!#$%&$'()*+!'+#!(+"!&+'),(--!-

!"#$%&'!"#$%& '()*+,$

Lasmiditan, Phase 3 Data inAcute Migraine Treatment ! !"#$%&'()*+',&--.$/'*0'1!2!3'4(5)6-7$'89213:! ;&-)</-+<'-/-&=-+<').>-&0-'->-+<0'),<-&'<#-',*&0<'.$0-?'!@@'/='4A!2B3:C'8@@'/='41D213:C'(5)6-7$'48D2A3:! E$0<'6$//$+'F-&-'.*GG*+-00C'()&-0<#-0*)C')+.'0$/+$5-+6-

! ;#-'5)0/*.*<)+ ).>-&0-'->-+<0')&-'5*H-5I'.%-'<$')6<*>)<*$+'$,'<#-'9"J;8K&-6-(<$&0C'F#*6#')&-'/$0<5I'6-+<&)5

! 9"J;8K &-6-(<$&0'.$'+$<'6)%0-'>)0$6$+0<&*6<*$+L'0$C'%+5*H-'<&*(<)+0C'<#*0'+-F'65)00'0#$%5.'7-'0),-'*+'<#-'(&-0-+6-'$,'>)06%5)&'.*0-)0-

82'M%6) NC'-<')52'!"#$%&%'(2'!@8OLP84!A:?-!!!!"-!!1!2'!2'Q*-<-6#) RSC'-<')52'S70<&)6<'TU"@!"8O@'(&-0-+<-.')<'VJW'!@8BL'X)+6$%>-&2'

!"#$!%#&!'!$"(#!)&(*+(",

CGRP! !"#$%&"&'()"*+",%-.(-.*'%*/0,/('%-(-*102(,3

! 40,/('%-(-! 523,(-! 5)$"-%2")#,,(-! 6-'"$2")(-

!"#$%&%&'%'&!(#

! '-.,

! 7"/"&'%$8*'90'*+(-)*%$*0$"*0/'(:0'")*+3*4;7<*0$"*&$"8"-'*'9$%#.9%#'*'9"*+%)3=*(-/,#)(-.*'9"*.#'

! <$"8"-'*0'*0,,*2(.$0(-"*&0'9%."-"8(8*8('"8*(-*'9"*'$(."2(-%:08/#,0$ 838'"2

! <,0820*,":",*(-/$"08"8*(-*2(.$0(-">*)"/$"08"8*?('9*'$"0'2"-'

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

!"#$%&'()!"#$$%"&$'()$'*(+,-*,'('-.&,*#/.#+&/0!.!

The Small Molecule CGRP Receptor Antagonists: Gepant SummaryAcute Treatment of Episodic Migraine (EM)§ There have been 6 gepants tested which demonstrated efficacy in acute

migraine treatment: olcegepant, BI 44370 TA, telcagepant, MK-3207, rimegepant, and ubrogepant

§ BI 44370 TA, telcagepant, and MK-3207 are all reportedly liver toxic§ Ubrogepant and rimegepant have reported out positive regulatory trials

and will likely be submitted to the FDA for acute treatment of migraine over the next year

§ 2-hour pain freedom ≈ 20% in phase 3 trials§ They do not cause vasoconstriction; unlike triptans, should be safe with

vascular disease1. Tfelt-Hansen P. Headache. 2011;51:118-123. 2. Tfelt-Hansen P, Do TP. Abstract PO-01-48 presented at IHC 2017; Vancouver. 3. Allergan press release. February 6, 2018. https://www.allergan.com/news/news/thomson-reuters/allergan-announces-positive-top-line-phase-3-resul. Accessed April 26, 2018. 4. Biohaven press release. March 26, 2018. http://biohavenpharma.com/biohaven-announces-successful-achievement-of-both-co-primary-regulatory-endpoints-in-two-pivotal-phase-3-trials-of-rimegepant-an-oral-cgrp-receptor-antagonist-for-the-acute-treatment-of-migraine/. Accessed April 26, 2018.

The Small Molecule CGRP Receptor Antagonists: Gepant Summary (cont.)Preventive Treatment of EM§ Atogepant vs placebo reported positive phase 2 trial data in 2018 and showed

drops in mean monthly migraine days for EM; will proceed to phase 3 trials§ No signal of liver toxicity§ Rimegepant will be tested for prevention in phase 2

1. Tfelt-Hansen P. Headache. 2011;51:118-123. 2. Tfelt-Hansen P, Do TP. Abstract PO-01-48 presented at IHC 2017; Vancouver. 3. Allergan press release. February 6, 2018. https://www.allergan.com/news/news/thomson-reuters/allergan-announces-positive-top-line-phase-3-resul. Accessed April 26, 2018. 4. Biohaven press release. March 26, 2018. http://biohavenpharma.com/biohaven-announces-successful-achievement-of-both-co-primary-regulatory-endpoints-in-two-pivotal-phase-3-trials-of-rimegepant-an-oral-cgrp-receptor-antagonist-for-the-acute-treatment-of-migraine/. Accessed April 26, 2018.

!"#$#%&'(%)*!"#$

MABs to CGRP or the CGRP Receptor for Migraine Prevention

! !"#$%&'$()'*$+,--'&'.($()%.$/&'0,"12$"&%3$4,5&%,.'$/&'0'.(,".6

! 7892$%&'$:,5$4"3';13'2$()%($;&"22$()'$:3""+$:&%,.$:%&&,'&$("$%$0'&*$24%33$'<('.(=>?

! 7892$%&'$'3,4,.%('+$:*$()'$&'(,;13"'.+"()'3,%3$2*2('4>$2"$."$&,2@$-"&$)'/%("("<,;,(*A2"$-%&>$

7892$%&'$2%-'=

! B--,;%;*$+%(%$2155'2($()%($/'&,/)'&%3>$."($;'.(&%3>$%.(,CDEFG$%;(,".$,2$21--,;,'.($

("$:3";@$4,5&%,.'$,.$2"4'$/%(,'.(2

!"#$$%&'$()*$(+,-./0%12#

$340%&'5')$'5#$%65789':;+0<,%12#

=H$I1$IJ>$K%((2$FJH$!"#$%&'"$()"#&*+,H$?L=MN=LOMPQRSTCRU?H$?H$V,/(".$F9>$'($%3H$-./!"#$%0%12H$?L=WN=R$O21//3RPQXMCX=LH$MH$Y'//'& XJH$3"(4(+'" ?L=WNSW$O21//3MPQ?MWC?USH$RH$Y'//'& XJH$3"(4(+'"/?L=WNSW$O21//3MPQ?UZC?TLH$

MABs to CGRP or the CGRP Receptor for Migraine Prevention (cont.)

! !"#$%&#'$()$*+,"-.#+#)%/012 !33$2! 4-"5$%-$,"#.#)%$671$871$()9$9#:"#(;#$%&#$)<+=#"$->$(:<%#$+#9*:(%*-);$%(5#)$*)$,(%*#)%;$?*%&$+#9*:(%*-)@-.#"<;#$&#(9(:&#

! A(.#$B<*:5$-);#%1$;#,("(%*)C$>"-+$,3(:#=-$?*%&*)$D$?##5$*)$,-;%$&-:$()(3';*;

! E&-?$:3*)*:(33'$+#()*)C><3$"#;,-);#$='$D$+-)%&! A(.#$"#;,-)9#"$"(%#;$>-"$FGHI$()9$&*C&#"! A(.#$;(>#%'$()9$%-3#"(=*3*%'$;*+*3("$%-$,3(:#=-! J#:"#(;#$(:<%#$+#9*:(%*-)$<;#$9(';1$*+,(:%1$()9$9*;(=*3*%'1$()9$*+,"-.#$B<(3*%'$->$3*>#$*)$:3*)*:(3$%"*(3;

DK$L<$LM1$4(%%;$NMK$!"#$%&'"$()"#&*+,K$OPD0QDPR0ST2HU@2GOK$OK$V*,%-)$NW1$#%$(3K$-./!"#$%0%12K$OPDXQD2$R;<,,32STE0@EDPK$0K$Y#,,#" EMK$3"(4(+'" OPDXQHX$R;<,,30STO0X@OGHK$2K$Y#,,#" EMK$3"(4(+'"/OPDXQHX$R;<,,30STOGZ@OUPK$

4 Injectable MABs to CGRP or Its Receptor:3 Now FDA Approved and Available

!"#$%&'()'**#+,%--. /%&'$0

1"#&'$#2%&'()3,"&+,%--.4/%&'$52#60

7'-8'$#2%&'()9$-&+/%&'$52#60

!:;5$#2%&'(+/%&'$52#60

!"#$%&$ '() *+,-.+ *+,-.+,-&./ *+,-.+,-&./ *+,-.+

0(#"&-12$-$(3%24

+(2"567-!.89,-:;9-<4

+(2"567-()-=#1)"&)67-!.>??@-<4-<(2"567,-()-A8@-<4-BC-<(2"53

+(2"567-!.>-?;9-<4-6(1$%24-$(3&,-"5&2-:?9-<4-!.-<(2"567-"5&)&1'"&)

BC-<(2"53-DE

F1)4&" .G0H-)&I&J"() .G0H-J&J"%$&-()-6%412$ .G0H-J&J"%$&-()-6%412$ .G0H-J&J"%$&-()-6%412$

0&4#61"()7-3"1"#3-

1<=)'::"*3#64>?@A?@B4,*"4&59"'5$#4

:"#3#$;5*$

1<=)'::"*3#6C?@D?@B4,*"4&59"'5$#4

:"#3#$;5*$

1<=)'::"*3#64C?EF?@B4,*"4&59"'5$#4

:"#3#$;5*$

G$46#3#-*:&#$;H:"#I#$;#64+J04:/'I#4K4!L4'$64ML4NMOI

O#"&IK 2L2&#)(6(4%I>-#<1ML'#667-5#<12>-N#<1ML5#<12%N&$>-5#<12L:99O>-5#<12%N&$LP9QP@O

&./L-&J%3($%I-I6#3"&)-5&1$1I5&R-0.F3L)12$(<%N&$-I6%2%I16-")%163R:R-F&JJ&) !SR !"#$#%&"R-?9:T>@T-U3#JJ6CVK?CTW?8@R-?R-F&JJ&) !SR-!"#$#%&"R-?9:T>@T-U3#JJ6CVK?8AW?P9R-CR-*$X%233(2 YR-!"#$#%&"R-?9:T>@T-U3#JJ6:VKCCQ;8R

3 Major MAB Questions

!"#$%&#'$()$*+,"-.#+#)%/ !"#$%&#'$0(1#/

!"#$%&#'$2*11#"#)%$%&()$3&(%$3#$&(.#$)-3/

Clinical Utility of the 4 MABs!"#$%&'()*+,*),,)-&*! !"#$%&#'('")*+,#-./0'1#+#234#1+5#('1)678/"#8"#*/"7.95#*8:(+8"'#1+5-#;(/*#,+-'98"'#7.(/):.#0''<-#=>?@#8"#7.'#A8B/7+9#C$D

! E7#?#5'+(#8"#7.'#/A'">9+,'9#'('")*+,#-7)15&#*'+"#*/"7.95#*8:(+8"'#1+5-#1(/AA'1#?F34#1+5-#;(/*#,+-'98"'

! G#"'0#*/"7.-#/;#"/#*8:(+8"'#6/*A+('1#087.#,+-'98"'#8"#-/*'#A+78'"7-! HA78"'I)*+,#-./0'1#+"#J#1+5#('1)678/"#;(/*#,+-'98"'#+7#?@#0''<-

+$.)&*+,*),,)-&! !"#A/-7#./6#+"+95-8-&#%EK-#-'A+(+7'#;(/*#A9+6',/#8"#9'--#7.+"#+#0''<#! L./0#*'+"8":;)9#698"86+9#,'"';87#8"#7.'#;8(-7#*/"7.

?3#D'AA'(#LM3#!"#$#%&" @F?JN4J#O-)AA9PQR@PJ>@S43#@3#D'AA'(#LM3#!"#$#%&" @F?JN4J#O-)AA9PQR@S2>@=F3#

Other Clinical Advantages

! !"#$%&'"()'%*+$,"-.+.%&! "#$%&'&()*+,#+%)&"*(#! /01%$'2.3,".($'2$).0"%.*('14$')$0,$"4$)-+./")01./2+,'.%,&/3+&/1+&))+&"0,*+$*13+4*'*/0$&(-+5'*$&/*60$&(-+2&)"&/*60$&(7

! 5##$0%.6$($44'7.%8'0*2*,-.)'.++($44$4'4108'"4')$9,$44.*('"()'"(:.$%&'4*'*/0$&(-+5'*$&/*60$&(-+2&)"&/*60$&(7

! ;"%.$(%',$9*,%$)'*1%0*2$4! 1.3&(.).,8-+.$%&",-+&/1+3&,.35&",.#/+&))+.$%'#9*1! <='4"#$%&'4*'*/0$&(-+5'*$&/*60$&(-+2&)"&/*60$&(7

:;+<*%%*' =>;+!"#$#%&" ?@:ABCA+430%%)D7!?DAE?FC;+?;+<*%%*' =>;+!"#$#%&" ?@:ABCA+430%%)D7!?FGE?H@;+

New Outcome Measures to Evaluate Migraine Treatment Effectiveness

!"#$%&&%'#()" !"#$#%&" *+!,-.,#/01&&2345*3,6*7."#*"#$%&&%'#()"#!"#$#%&" *+!,-.,#/01&&2345*786*9+"#3"#:;&<=>#?@#%<#A2"#!"#$#%&""#*+!,-.,#/01&&2*45!8*6!83"

!"#$%&'("#)"*)+,&"#(+)-")./)0%&%#12345)*&%23#%612345)738+3#%612349

!"#$%&'("#)"*)3+1-%)2%:(+3-("#)"$%&1'%)-")#")"$%&1'%)0%&%#12349

§ Effectiveness in patients with lack of response to previous preventive medications§ Prospective placebo-controlled randomized clinical trials of 2-4 previous

preventives (erenumab LIBERTY trial and fremanezumab FOCUS study) § Subanalyses (erenumab, fremanezumab, galcanezumab)§ Specific exposures: fremanezumab and patients with a lack of success

with onabotulinumtoxinA and topiramate

Clinically Meaningful Outcome Measures

1. Tepper SJ. Headache 2018;58 (suppl3):238-275. 2. Tepper SJ. Headache 2018;58 (suppl3):276-290. 3. https://www.tevapharm.com/news/teva_announces_positive_topline_phase_iiib_results_with_fremanezumab_in_adults_with_migraine_who_did_not_respond_to_multiple_classes_of_preventive_treatments_12_18.aspx. Accessed December 24, 2018. Ï

§ Overall responder rates§ 41% of patients showed ≥75% responder rates of reduction in mean

monthly migraine days at 1 year in the erenumab open-label extension trial§ 54% showed ≥75% responder rates of reduction in mean monthly migraine

days at 1 year in the eptinezumab placebo-controlled RCT§ The ≥75% responder rates are linked to marked drops in disability and

impact and improvements in quality of life in clinical trial data

1. Tepper SJ. Headache 2018;58 (suppl3):238-275. 2. Tepper SJ. Headache 2018;58 (suppl3):276-290. 3. https://www.tevapharm.com/news/teva_announces_positive_topline_phase_iiib_results_with_fremanezumab_in_adults_with_migraine_who_did_not_respond_to_multiple_classes_of_preventive_treatments_12_18.aspx. Accessed December 24, 2018. Ï

Clinically Meaningful Outcome Measures (cont.)

How Are They Given?! !"#$%&'( '$)*+',-'$#.%&'(/*0#,123$4#-5*&6$57,8! 9"#&'$#.%&'(/*0#,123$4#-5*&6$57,8*6"*#:#"8*;*&6$57<! !=53$#.%&'(/*>#-#3:#*'$*?@*3$1%<36$*#:#"8*;*&6$57<

!"#$%&'( )*+,-.%+/*$0#1+/"A,<6*%<#)*16"*#5'$#"-#=5 16"*"7#%&'563)*'"57"353<B*'$)*6$#*61*57#*+#$#"3-*<%&'5"3=5'$ 3$4#-536$*="6)%-5<

3$4#-5*&6$57,8*6"*#:#"8*;*&6$57<

2/32#'4-*$0#1+*/$-(%++/$

5/16-"*$7

5/168%$4/16-9:&(/49

;#<*1*$#

=4#'"-('9#

>'9#-1'3

?'41'$#@%&'( )*+,-.%+/*$0#1+/"A,<6*%<#)*16"*)%,'+,%53)#*16"*CDE*'$)*3F#G3.%&'( 16"*=<6"3'<3</"-3"#A*44#<-9:"*$7#-

B"#&'$#@%&'()*+,-C"#A*44#<-D:"*$7#

CDEH)3'(#5#<*&#,,35%<*58=#*EI

Summary! !"#$%&$'()%*%+',$"(,*-.,#%,&$"/0"1%*%+'2,3$)1$,)(,

#/"4(*"#)%4"*,/-(-"/1$,0".-,/-"*! 5)+/")4-,)(,%4-,%6,#$-,0%(#,.)("7*)4+,.)(%/.-/(,)4,#$-,3%/*.

! 840-#,4--.,)(,$)+$2,3)#$,&"#)-4#(,.)(1%4#)49)4+,19//-4#,%/"*,&/-:-4#):-,0-.)1"#)%4(,0%/-,#$"4,;<=,%6,#$-,#)0-,7',#$-,-4.,%6,",'-"/

! >-3,.-()+4-/,1*"((-(,%6,"19#-,0-.)1"#)%4,"/-,)4,.-:-*%&0-4#

! ?-&"4#(2,(-/%#%4)4,@ABCDEFG,"+%4)(#! >-3,1*"((-(,%6,&/-:-4#):-,0-.)1"#)%4,"/-,":")*"7*-,"4.,

)4,.-:-*%&0-4#! ?-&"4#(! H4#)BI?J!,%/,I?J!,/-1-&#%/,5HK(

! >-3,0-"(9/-(,%6,-66-1#):-4-((,(9++-(#,0"/L-.,)0&/%:-0-4#(,)4,%9#1%0-(,3)#$,#$-,4-3,5HK(

%/"*,&/-:-4#):-,0-.)1"#)%4(,0%/-,#$"4,;<=,%6,#$-,#)0-,

!"#"$%&'(&)$*+,#-&.%&+(##/ .%/$&',/0%'

!"#$%#&$#'($!"#$%&'(%)*#+'*(+$*)+

!"##$%!&'"(")*%+,*%-./0,-./012.3#45..26#7/58509/#:.2;.5<,-./012.#%=>51-/=1#)/?.2@2;A3#B1C#D2E/>9FE#72E>-15@#5=8#$/8-05@#G/=1/.45..26#)/?.2@2;-05@#%=E1-1?1/:92/=-H3#(.-I2=5

!"#$%&

Case 1! !" #$%&"%'%()*+,'-*./0%1.2'3%1&45%

0,6-,""&.37%'38&,4+7%9'+3':0;"%0&",'",7%'30%5,'0'<5,"%"&3<,%<5&/05..0

! =5,%'44'<>"%.<<:-%1,,>/+%'30%'-,%?,3,-'//+%(%0'+"%&3%0:-'4&.3

! =5,+%'-,%.@4,3%4-&??,-,0%A+%"4-,""7%@'4&?:,7%'30%2,3","

! B,'0'<5,"%'-,%6-,<,0,0%A+%'%6-.0-.2,%.@%C%0'+%.@%<.?3&4&D,%@:EE&3,""%'30%2'/'&",%A:4%3.%4-:,%':-'

F#GD&4'/%"&?3"$%HIGA/..0%6-,"":-,$%IG6:/",$%9G-,"6&-'4.-+%-'4,$

Case 1 (cont.)! !"#$%$&"'"#$&%'"(%)*%"##+,-".)&'%/(%

0$1+//).23%/)4"0&1"4%,+'&1"0&%0+%*&5&1&%-").3%-$+0+6 ".'%-$+.+-$+/)"3%".'%."7*&"%8)0$%91&:7&.0%')*"/)4)0(%".'%8+1;%4+**

! <=>%?@%ABCDEC3%@%EB3%F%ABG%#+,-4&0&%,&')#"4%".'%.&71+4+2)#%&H",*%"1&%.+1,"4

! I#70&4(3%*$&%2&0*%1&4)&9%8)0$%*7,"01)-0".%ACC%,2%@J%/70%7*7"44(%$"*%1&#711&.#&%0$"0%1&:7)1&*%1&01&"0,&.0

! K+1%-1&5&.0)+.3%*$&%$"*%01)&'%",)01)-0(4).&3%8$)#$%#"7*&'%&H#&**)5&%*&'"0)+.3%".'%0+-)1","0&3%8$)#$%#"7*&'%8+1'69).').2%')99)#740(

<=L5)0"4%*)2.*M%?@L/4++'%-1&**71&M%@L-74*&M%FL1&*-)1"0+1(%1"0&M

What Is Her Diagnosis? !"#$%"&#'("&)*+)&,,'-'.&#'("*(-*/$&0&.1$*2',(%0$%,*3!+/2456*2'&7"(,#'.*+%'#$%'&*-(%*89',(0'.*:'7%&'"$*;'#1(<#*=<%&

!"#!$#%&'($#)*+&#'$$',-(#).%)*%%*/0#,1*$&1*'#234

2"#5&'6',7&#'$$',-(#%'($*/0#839:#7;.1(#<=7&/#./$1&'$&6#;1#./(.,,&(().%%>#$1&'$&6?#

@"#5&'6',7&#7'(#'$#%&'($#:#;)#$7&#);%%;=*/0#8#,7'1',$&1*($*,(AB" C/*%'$&1'%#%;,'$*;/:" D.%('$*/0#E.'%*$>F" G;6&1'$&#;1#(&+&1&#H'*/#*/$&/(*$>8" !001'+'$*;/#I>#;1#,'.(*/0#'+;*6'/,&#;)#1;.$*/&#H7>(*,'%#',$*+*$>#<&0J#='%-*/0#;1#,%*KI*/0#($'*1(?

4" 4.1*/0#7&'6',7&#'$#%&'($#B#;)#$7&#);%%;=*/0AB" L'.(&'#'/6M;1#+;K*$*/0:" D7;$;H7;I*'#'/6#H7;/;H7;I*'

N"#L;$#I&$$&1#',,;./$&6#);1#I>#'/;$7&1#O@543F#6*'0/;(*(

!"#$%&%&'(%) :PBQRFQ<B?AB3:BB"

Options: Classification of Migraine Preventive Therapies AAN AHS Guidelines, 2012

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

!"#"$%&'%()*%+$,--%.%/01,$-2

&3/1"41$"4/15%6078-!"#$

%&'()*+*,-$

9:;$<5="0-.-,&')&/&/

")&')*0&/&/$

%(+&/&/$

&$$%<>%/?"%@&A-%?,#"%!"#"$%&%,-%<>%*BCD'%%%%1)-02+*3$444

5)-+*0-62+*3$44

7*/8*0-62+*3$

!"#"$%A'%E0<;,;$F%">>"5/1#"%(C%5$,--%.%<0%*%5$,--%..%-/761"-2

&3/16"40"--,3/-#+(,)(',9/(0-

!-0/*:*;(0-

9:;$<5="0-#,-0&/&/

<*=&/&/

!"#"$%+'%E<--1;$F%">>"5/1#"%(C%5$,--%..%-/76F2

&+G%13?1;1/<0->(?(0&')(/

9:;$<5="0-<-3(@&/&/

"(0=&/&/

&HA-A*0=-?*),*0B

&3/1?1-/,I13"-A9')&C-',*=(0-

J$6%6,/,KI"6-A/&0(=(0-D472*0:*8(0-D444

!"#"$%L'%.3,6"M7,/"%<0%5<3>$15/138%6,/,%/<%-744<0/%<0%0">7/"%7-"

+,0;<315%13?1;1/<0-G*8-,*6&/*+(=-

&3/1/?0<I;</15-GH*):*)(0

NNH.-G:/2&;-,(0-D4:/2@&;*+(0-

9:;$<5="0-G3(?&')&/&/

O+&-G')&,)(',9/(0-

&GP-G7E"

++A-!-)*'*+(/D40(8*)=('(0-D40(+&=('(0-D44

0(:-=('(0-

@7-5$"%0"$,Q,3/-G898/*0=-/*,-

E<--1;$F%<0%40<;,;$F%13">>"5/1#"

1?,*3/(?C-=4*?40&,4-::-8,(@-

&GP-G>%7

")&3*3/940&,4-::-8,(@-

O+&-G8/&+(')*+(0-

"&??(3/940&,4-::-8,(@-

&GP-GIJAE

ARP-G8/&0*6-'*+

9:;$<5="0-G*8-32,&/&/

SN&.P-G0*32+-,&0-

&HA-G,-/+(?*),*0

What Are Your Considerations in Picking Medication Options for Her? ! !"#$#%&$#%'%(&)*$%+&,#-*$.#/%*0%1$#2#3,.2#%(#4.+&,.*3/%0*$%56%1$#2#3,.*37

! !"#$%&'(&))*"#)+83*3#%9:;<&11$*2#4=! !"#$,-'&(#&")$.&) 81$*1$&3*>*>%&34%,.(*>*>%9:;<&11$*2#4=! !/0) 84.2&>1$*#?%&34%,*1.$&(&,#%9:;<&11$*2#4=

! @#$%A>**4%1$#//B$#%./%*3%,"#%>*C%/.4#D%AB,%3*,%1$*".A.,.2#>E%/*

! :#1$#//.*3%&34%F&E3&B4G/%4./#&/#%(.,.-&,#%&-&.3/,%H<A>*+I#$/

! !"#$#%./%#2.4#3+#%0*$%#00#+,.2#3#//%*0%+&34#/&$,&3%JK%(-%.3%56%1$#2#3,.*3

! L#%/,&$,#4%"#$%*3%+&34#/&$,&3%M%(-%NO%P@Q%C##I%JD%,"#3%.3+$#&/#4%,*%JK%(-%NO%P@Q%C##I%R%0*$%&%'<(*3,"%,$.&>

P@QS#2#$E%3.-",%&,%A#4,.(#T%JT%!$*32.I 5D%#,%&>T%!"#"T%RUU'VRMW8J=7KX<KWT%RT%Q,*23#$ YZD%#,%&>T%$%&'()()*+(T%RUJ[V'[8\=7XR'<X'RT

Candesartan Made Her Light-Headed and Was Not Tolerated. Now What? ! !""#$%&'$%'($%)'*+"','(-./0'1-*"&/0$"2'/3'#0"4"%*$4"'(")$1-*$/%2'3/0'567

! !"#$%&'()#("*$+(*,-').')/".0.0,/"1,#$2.0.0,34!5/'').+(167 2+"'1-%8*'*-9"'*+"':"*-':;/19"02'-%)'1-%8*'*/;"0-*"'*+"'1-%)"2-0*-%<'4"0-#-($;'+-2'4"0=';/>'"4$)"%1"'3/0'"33"1*$4"%"22?'2/'*+$2'1-*"&/0='>$;;'%/*':"'/@0'%"A*'2*"#

! !84*,-1$+/0').(9,/"1,#.'$)/2/#(,34!5/'').+(167 :/*+'/@*! B$4-;#0/"AC4-;#0/-*"'$2'1/%*0-$%)$1-*")'$%'>/("%'/3'1+$;)D:"-0$%&'#/*"%*$-;')@"'*/'0$29'/3'#/;=1=2*$1'/4-0$"2'-%)':$0*+')"3"1*2<

)$21@22'#;-%2'*/'1/%1"$4"'-%)'@2"'/3':$0*+'1/%*0/;'! !"#$1(')(**/"#*,-"."(,34!5/'').+(167 -($*0$#*=;$%"'/@*

! E+"'1/(:$%-*$/%'/3')"#0"22$/%'-%)'-%A$"*='>/@;)'-;;/>'3/0'-%'FGHI<'*+"0"'$2';"4";'J'"4$)"%1"'3/0'4"%;-3-A$%"

! E+"0"'$2';"4";'K'"4$)"%1"'3/0'LK5'$%+$:$*/02

! M+-*'-:/@*'*+"'#0/:;"('/3'0"1@00"%1"'>$*+'*+"'2@(-*0$#*-%N

! L29'-:/@*')/2"?'3/0(@;-*$/%?'-%)'*$($%&

! L))$*$/%'/3'-%'GFLIB'>$*+'*+"'*0$#*-% 1-%'0")@1"'0"1@00"%1"'-%)'&$4"'&0"-*"0';$9";$+//)'/3'-'2@2*-$%")'#-$%D30""'0"2#/%2"

FGHIO2"0/*/%$%'%/0"#$%"#+0$%"'0"@#*-9"'$%+$:$*/0PQP'J@;@* F?'"*'-;P'!"#$ %&'()" %&'()*'(+P'RSST<QSUVQW7TTDTXP RP'YZ=-;1$% FG?'"*'-;P',&-.-/0&P'RSS[<T[VRW7QTTDQ[RPP

Next Steps! !"#$%&%'(#")*+,-)./)01)234)5%6)(#(7(%7"8)&9:);:"<"#7(9#

! =>.%7:(;7%#?#%;:9'"#)698(>.)@9.A(#%7(9#)7%A$"7)5%6)67%:7"8)&9:)%@>7")7:"%7."#7

! BC")%@>7")7:"%7."#7)(#@:"%6"8)7C")$(D"$(C998)9&);%(#)&:""89.):%7C":)7C%#)E>67):"$("&F)%#8):"8>@"8)8>:%7(9#)9&).(/:%(#")%77%@D6)79)9#")8%G)%A9>7)HI*)9&)7C")7(."F)%)A(/)(.;:9<"."#7

! BC")<"#$%&%'(#"):"8>@"8).(/:%(#")&:"J>"#@G)AG)K-LM)%#8)C"$;"8)A97C)8";:"66(9#)%#8)%#'("7GN9;7(.%$O

! =9.")6@"#%:(96)&9:)5C(@C)7C");:9<(8":)6C9>$8)A");:";%:"8P! BC")@9.A(#%7(9#)6>.%7:(;7%#?#%;:9'"#)698(>.)89"6)#97)%@C("<")6>67%(#"8);%(#)&:""89.)(#)K-LM)

9&)%77%@D6N#95)5C%7Q! BC")<"#$%&%'(#")@%>6"6)6"'>%$)8G6&>#@7(9#)%#8)(#69.#(%)(#)69.");%7("#76N#95)5C%7Q

234R"<":G).9:#(#/,

Considerations for Next Steps

!"#$%&'()%*(+,("*-.-&#$%&! !"#$%&'()*+,-$.#/#0'1.$21&1/31&%3$%&'(4156$#.#&72%4 %&5$'"#$%&'()*+,-$21&1/31&%3$%&'(415(#8$9.#2%&#:72%4 %&5$;%3/%&#:72%4 %.#$%00.1<#5$91.$2(;.%(&#$0.#<#&'(1&=$41'"$#0(815(/$%&5$/".1&(/

! !"#6$%.#$%00.10.(%'#$91.$78#$(&$0%'(#&'8$>('"$%$3%/?$19$87//#88$>('"$'"#$@)A$/%'#;1.(#8$19$0.#<#&'(<#$2#5(/%'(1&$%&5$8(;&(9(/%&'$5(8%4(3('6

! !"#$&#7.121573%'(1&$5#<(/#8$0.1<(5(&;$#B'#.&%3$'.(;#2(&%3$&#.<#$8'(273%'(1&$C#!DEF$%&5$8(&;3#$0738#$'.%&8/.%&(%3$2%;&#'(/$8'(273%'(1&$C8!GEF$%.#$41'"$HIJ)/3#%.#5$91.$0.#<#&'(1&$19$2(;.%(&#$%&5$91.$%/7'#$'.#%'2#&'$19$2(;.%(&#$%&5$/1735$>1.?$91.$41'"$0.143#28

Considerations for Next Steps (cont.)

!"#$%&'()%*(+,-#.(#*.+#/.&#(%)(01! !"#$%&#$'("%)$*(%*&+%,-' './)(,'(-,*,%*&+%,- "*(0*"1,%*&+%,- /,-(2$($00$/%&1$(3&%)("*(3&%)".%(,(/"-/"#&%,-%(4!567(,%(,/)&$1&-8(*$9./$9(*$/.**$-/$(*,%$'

! 7:;(2<('$=0>&-?$/%&"-("*(-,',=('+*,<(),'('.+$*&"*('.'%,&-$9(2$-$0&%(,-9(#&8)%(,99*$''(%)$(&''.$("0(*$/.**$-/$! @$&8)(%)$(*&'AB2$-$0&%

! C)$(D(-$.*"#"9.=,%&"-(9$1&/$'(#$-%&"-$9(,2"1$E(+=.'(%)$(-"-&-1,'&1$(1,8,=(-$*1$('%&#.=,%"*(F-G4!H(,*$(,==(I75>/=$,*$9(0"*(,/.%$(%*$,%#$-%("0(#&8*,&-$